<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056134</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000270762</org_study_id>
    <secondary_id>ERLANGEN-ONTAK</secondary_id>
    <secondary_id>EU-20246</secondary_id>
    <nct_id>NCT00056134</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma</brief_title>
  <official_title>Vaccination of HLA-A1 and/or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide-Loaded Autologous Dendritic Cells With Prior Depletion of CD25-Positive Cells Using Denileukin Difitox (ONTAK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make&#xD;
      the body build an immune response to kill tumor cells. Biological therapies such as&#xD;
      denileukin diftitox may be able to deliver cancer-killing substances directly to melanoma&#xD;
      cells. Combining vaccine therapy with biological therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of combining vaccine therapy with&#xD;
      denileukin diftitox in treating patients who have stage III or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of vaccination with autologous dendritic cells pulsed with tumor&#xD;
           and influenza antigen peptides with or without ex vivo CD40-ligand and denileukin&#xD;
           diftitox, in terms of tumor-specific T-cell response, in patients with HLA-A1- and/or&#xD;
           HLA-A2.1-positive stage III or IV melanoma.&#xD;
&#xD;
        -  Determine the safety and tolerability of these vaccinations in these patients.&#xD;
&#xD;
        -  Determine tumor response in patients treated with these vaccinations.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Phase I (Administration of denileukin diftitox and vaccinations #1 to #4): Patients&#xD;
           undergo leukapheresis for collection of peripheral blood mononuclear cells (PMBC). PBMC&#xD;
           are processed for the generation of dendritic cells (DC) to be used for vaccinations. DC&#xD;
           are pulsed with HLA-A1- and HLA-A2.1-restricted peptides derived from&#xD;
           melanoma-associated tumor antigens. DC are pulsed with or without ex vivo treatment with&#xD;
           CD40-ligand. Patients receive denileukin diftitox IV for 3 consecutive days before the&#xD;
           first vaccination. Patients receive 4 pulsed DC vaccinations subcutaneously (SC) on days&#xD;
           1, 14, 42, and 70 in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who show a tumor response (at least stable disease) may receive vaccination #5 and&#xD;
      further booster vaccinations.&#xD;
&#xD;
        -  Phase II: DC are generated and pulsed as in phase I. Patients receive up to 6 additional&#xD;
           booster pulsed DC vaccinations SC on days 126, 184, 268, 356, 520, and 692 in the&#xD;
           absence of disease progession or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for 10 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 8-30 patients will be accrued for this study within 6-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by clinical and laboratory evaluation at every visit</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival as assessed by clinical staging (CT scan and positron emission tomography [PET]) every 3 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depletion of regulatory T-cells as assessed by tetramer stainings at every visit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of antigen-specific immune responses as assessed by elispot and tetramer staining at every visit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression as assessed by clinical staging (CT scan and PET) every 3 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as assessed by clinical staging (CT scan and PET) every 3 months</measure>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cell vaccine plus denileukin difitox</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed locoregional or metastatic cutaneous malignant melanoma&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
                    -  Stage III: pT4b, N0, M0 (satellite metastases) or any pT, N1 or pT, N1 or&#xD;
                       N2a-c, M0 (lymph node metastases or in transit intralymphatic metastases)&#xD;
&#xD;
                    -  Stage IV: any pT, N1-2, M1a-b&#xD;
&#xD;
                    -  Surgically incurable&#xD;
&#xD;
                    -  Incurable with standard treatment (i.e., localized chemotherapy/limb&#xD;
                       perfusion for stage III, systemic chemotherapy for stage IV)&#xD;
&#xD;
          -  Unidimensionally or bidimensionally measurable disease by physical examination (e.g.,&#xD;
             cutaneous metastases) and/or non-invasive radiologic procedures NOTE: Stage III&#xD;
             lesions may be measurable lymph nodes after incomplete resection and/or inoperable in&#xD;
             transit metastases&#xD;
&#xD;
          -  HLA-A1 and/or HLA-A2 expression by serologic HLA typing&#xD;
&#xD;
               -  HLA-A2.01 subtype must be confirmed by polymerase chain reaction on genomic DNA&#xD;
                  obtained from peripheral blood mononuclear cells&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
               -  Previously treated CNS metastases (e.g., excision of a single metastasis) allowed&#xD;
                  if no active disease present by CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 2,500/mm^3&#xD;
&#xD;
          -  Neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count greater than 700/mm^3&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dL&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  No hepatitis B or C&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically significant respiratory disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No immunodeficiency disease&#xD;
&#xD;
               -  No evidence of HIV-1, HIV-2, or human T-cell lymphocytic virus-1&#xD;
&#xD;
          -  No active autoimmune disease including, but not limited to:&#xD;
&#xD;
               -  Lupus erythematosus&#xD;
&#xD;
               -  Autoimmune thyroiditis or uveitis&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Inflammatory bowel disease NOTE: Vitiligo allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks after study&#xD;
             participation&#xD;
&#xD;
          -  No organic brain syndrome or significant psychiatric abnormality that would preclude&#xD;
             study participation and follow-up&#xD;
&#xD;
          -  No contraindication to leukapheresis&#xD;
&#xD;
          -  No other active malignant neoplasms&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior systemic immunotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy during and for 2 weeks after last vaccination&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior systemic chemotherapy (6 weeks for nitrosoureas [e.g.,&#xD;
             fotemustine])&#xD;
&#xD;
          -  No concurrent chemotherapy during and for 2 weeks after last vaccination&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent corticosteroids during and for 2 weeks after last vaccination&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the spleen&#xD;
&#xD;
          -  Concurrent palliative radiotherapy allowed for selected metastases (e.g., pain or&#xD;
             local complications such as compression)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  No prior organ allografts&#xD;
&#xD;
          -  Concurrent surgery of selected metastases (e.g., pain or local complications such as&#xD;
             compression) allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational drugs during and for 2 weeks after last&#xD;
             vaccination&#xD;
&#xD;
          -  No concurrent paramedical substance during and for 2 weeks after last vaccination&#xD;
&#xD;
          -  No concurrent participation or intent to participate in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerold Schuler</last_name>
    <role>Study Chair</role>
    <affiliation>Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Erlangen</investigator_affiliation>
    <investigator_full_name>PD Dr. med. univ. Beatrice Schuler-Thurner</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Publication</doc_type>
      <doc_url>https://www.ncbi.nlm.nih.gov/pubmed/23958949</doc_url>
      <doc_comment>Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.&#xD;
Baur AS1, Lutz MB, Schierer S, Beltrame L, Theiner G, Zinser E, Ostalecki C, Heidkamp G, Haendle I, Erdmann M, Wiesinger M, Leisgang W, Gross S, Pommer AJ, KÃ¤mpgen E, Dudziak D, Steinkasserer A, Cavalieri D, Schuler-Thurner B, Schuler G.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>DOI:10.1182/blood-2012-09-4569</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.ncbi.nlm.nih.gov/pubmed/23958949</doc_url>
      <doc_comment>Denileukin diftitox (ONTAK) induces... Baur AS et al</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

